ArticleVirulence2025
Human bocavirus NP1 antagonizes host type I interferon response through repressing the nuclear transport of STAT1.
Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NUP85 as a Pan-Cancer Immune Biomarker: Integrated Multi Omics and Functional Analyses Reveal Its Role in Tumor Prognosis.ImmunoTargets and therapy · 2026Article
- Human bocavirus NP1 antagonizes host type I interferon response through repressing the nuclear transport of STAT1.Virulence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human bocavirus 1 (HBoV1), first identified in human nasopharyngeal specimens in 2005, is a relatively recent member of the respiratory virus family and is primarily associated with respiratory tract infections. Despite this, the mechanisms underlying HBoV1 pathogenesis remain poorly understood, primarily due to the lack of suitable cell lines and animal models, as well as the complicating factor of co-infections with other pathogens. In this study, we demonstrate that the non-structural protein 1 (NP1) of HBoV1 antagonizes the type I interferon (IFN-I) signaling pathway. NP1 interacts with the DNA-binding domain (DBD) of signal transducer and activator of transcription 1 (STAT1) and the importing β-binding (IBB) domain of karyopherin subunit alpha-1 (KPNA1), thereby disrupting the formation of the STAT1/KPNA1/KPNB1 complex and subsequently inhibiting STAT1 nuclear translocation, a critical step in IFN-I signaling. Furthermore, we show that HBoV1 NP1 facilitates the replication of influenza A virus (IAV) and respiratory syncytial virus (RSV). These findings suggest a novel mechanism by which bocavirus proteins antagonize the host's innate immune response and provide new evidence that bocavirus may exacerbate the symptoms of clinical respiratory viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.